Laddar...
Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report
SMARCA4‐deficient thoracic sarcoma (SMARCA4‐DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4‐DTS have not yet been developed. Most recently, anti‐programmed cell death 1 receptor (PD‐1) blockade h...
Sparad:
| I publikationen: | Thorac Cancer |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
John Wiley & Sons Australia, Ltd
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6885443/ https://ncbi.nlm.nih.gov/pubmed/31617320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13215 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|